Compare PLXS & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLXS | BLTE |
|---|---|---|
| Founded | 1979 | 2018 |
| Country | United States | United States |
| Employees | 20000 | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 6.0B |
| IPO Year | 1995 | 2021 |
| Metric | PLXS | BLTE |
|---|---|---|
| Price | $274.70 | $158.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $206.50 | $198.00 |
| AVG Volume (30 Days) | ★ 303.1K | 143.1K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 56.11 | N/A |
| EPS | ★ 3.32 | N/A |
| Revenue | N/A | ★ N/A |
| Revenue This Year | $14.31 | N/A |
| Revenue Next Year | $8.29 | $492.11 |
| P/E Ratio | $83.37 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $126.86 | $60.00 |
| 52 Week High | $307.06 | $200.00 |
| Indicator | PLXS | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 58.19 | 54.65 |
| Support Level | $269.81 | $145.11 |
| Resistance Level | $300.15 | $160.72 |
| Average True Range (ATR) | 12.06 | 5.85 |
| MACD | 3.04 | 0.04 |
| Stochastic Oscillator | 93.94 | 64.74 |
Plexus Corp designs, manufactures, and services complex products in demanding regulatory environments, supporting life-saving medical devices, mission-critical aerospace and defense products, industrial automation systems, and semiconductor capital equipment. Its integrated lifecycle solutions span design and development, supply chain solutions, new product introduction, manufacturing, and sustaining services for market and disruptive companies in the Aerospace/Defense, Healthcare/Life Sciences, and Industrial sectors. The Company operates through three reportable segments: AMER, APAC, and EMEA, with the majority of revenue from the APAC segment.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.